{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:18:12Z","timestamp":1763018292082,"version":"3.41.2"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Peginterferon beta-1a administered every 2 weeks via subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated injection site reactions (ISRs) can lead to treatment discontinuation. Prior studies with interferon beta-1a reported a lower frequency of ISRs with intramuscular (IM) administration than with SC administration. IM administration of peginterferon beta-1a may therefore represent a useful alternative treatment option. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> A phase\u2009I, open-label, two-period crossover study randomized healthy volunteers to receive a single dose of peginterferon beta-1a 125\u2009mcg administered IM followed by a single 125\u2009mcg dose administered SC after a 28-day washout or vice versa. Blood samples were collected up to 504\u2009h post dose to determine pharmacokinetic (PK) and pharmacodynamic (PD) profiles. The primary endpoint was assessment of bioequivalence based on maximum serum concentration (C<jats:sub>max<\/jats:sub>) and area under the curve from time zero extrapolated to infinity (AUC<jats:sub>inf<\/jats:sub>). Other PK parameters, as well as PD (serum neopterin) and safety profiles, were also evaluated. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> The study enrolled 136 participants. Bioequivalence of IM and SC peginterferon beta-1a was established for both C<jats:sub>max<\/jats:sub> ([least squares (LS)] mean IM\/SC ratio: 1.083 [90% confidence interval (CI), 0.975\u20131.203]) and AUC<jats:sub>inf<\/jats:sub> (LS mean IM\/SC ratio: 1.089 [90% CI, 1.020\u20131.162]). Other PK and PD parameters were similar between administration routes, although moderate to high inter-subject variability was observed for IM and SC. Safety profiles were generally balanced between IM and SC administration. ISRs occurred at a lower frequency with IM [14.4% (95% CI, 8.89\u201321.56%)] than with SC [32.1% (95% CI, 24.29\u201340.70%)] administration ( p\u2009=\u20090.0005). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> These results demonstrate bioequivalence between peginterferon beta-1a IM and SC and support the consideration of IM injection of peginterferon beta-1a as a viable treatment option in patients with RRMS and RMS. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1756286420975227","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T10:20:57Z","timestamp":1611310857000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers"],"prefix":"10.1177","volume":"14","author":[{"given":"Yuan","family":"Zhao","sequence":"first","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Ramia","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta","family":"Sahu","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achint","family":"Kumar","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Naylor","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Naik","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheri\u00e9 L.","family":"Butts","sequence":"additional","affiliation":[{"name":"Biogen, 225 Binney St., Cambridge, MA 02142,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"bibr1-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.07.011"},{"key":"bibr2-1756286420975227","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7070078"},{"key":"bibr3-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.10.001"},{"key":"bibr4-1756286420975227","unstructured":"Plegridy\u00ae (peginterferon beta-1a) [summary of product characteristics]. Cambridge, MA: Biogen, Inc, 2019."},{"key":"bibr5-1756286420975227","unstructured":"Plegridy\u00ae (peginterferon beta-1a) [prescribing information]. Cambridge, MA: Biogen, Inc, 2015."},{"key":"bibr6-1756286420975227","unstructured":"European Medicines Agency. Plegridy [peginterferon beta-1a]: authorisation details, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/plegridy#authorisation-details-section (accessed 16 November 2019)."},{"volume-title":"Presented at ACTRIMSECTRIMS","author":"Hua LH","key":"bibr7-1756286420975227"},{"key":"bibr8-1756286420975227","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2015-042"},{"key":"bibr9-1756286420975227","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2016-0032"},{"key":"bibr10-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514557986"},{"key":"bibr11-1756286420975227","unstructured":"Avonex\u00ae (interferon beta-1a) [prescribing information]. Cambridge, MA: Biogen, Inc, 2015."},{"key":"bibr12-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08430-1"},{"key":"bibr13-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-144"},{"key":"bibr14-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512438239"},{"key":"bibr15-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000034080.43681.DA"},{"key":"bibr16-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03110.x"},{"key":"bibr17-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1159\/000323216"},{"key":"bibr18-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011407068"},{"key":"bibr19-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12968"},{"key":"bibr20-1756286420975227","unstructured":"Guidance for Industry. Bioavailability and bioequivalence studies submitted in NDAs or INDs\u2014general considerations. Rockville, MD: Department of Health and Human Services, CDER Office of Clinical Pharmacology, 2014."},{"key":"bibr21-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390304"},{"key":"bibr22-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.630720"},{"key":"bibr23-1756286420975227","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2013.19.s1.S24"},{"key":"bibr24-1756286420975227","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S130334"},{"key":"bibr25-1756286420975227","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12521"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420975227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756286420975227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420975227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T19:53:17Z","timestamp":1740858797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756286420975227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"alternative-id":["10.1177\/1756286420975227"],"URL":"https:\/\/doi.org\/10.1177\/1756286420975227","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"type":"print","value":"1756-2864"},{"type":"electronic","value":"1756-2864"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"1756286420975227"}}